Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PeptiSleep is a natural, plant-derived bioactive peptide ingredient developed by Nuritas using an AI-driven discovery platform[3][5][7][8]. It is sourced from rice bran protein and specifically designed to support all phases of sleep, enhancing both the quantity and quality of sleep—including deep and REM stages—without causing sedation or morning grogginess[3][5][7]. Mechanistically, PeptiSleep acts by modulating cortisol (helping to reduce stress-related hyperarousal) and downregulating the orexin (hypocretin) pathway, which calms the central nervous system and facilitates natural sleep onset and maintenance[1][8]. Clinically, PeptiSleep has demonstrated statistically significant improvements in measures such as sleep duration, sleep onset latency, sleep quality, and heart rate variability, supporting its role in promoting restorative sleep and balanced circadian rhythm[3][5][6][7]. It is a melatonin-free alternative, formulated for both dietary supplement and functional food applications, and can be found in numerous consumer products[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PeptiSleep.